Research programme: cannabinoid receptor CB2 agonists - Arena PharmaceuticalsAlternative Names: AR-XYZ
Latest Information Update: 03 May 2016
At a glance
- Originator Arena Pharmaceuticals
- Mechanism of Action Cannabinoid receptor CB2 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis; Pain
Most Recent Events
- 03 May 2016 Discontinued - Preclinical for Pain in USA (PO)
- 03 May 2016 Discontinued - Early research for Osteoarthritis in USA (PO)
- 26 Apr 2012 Preclinical trials in Pain in USA (PO)